Cutler Group LP Cytom X Therapeutics, Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$1.48 - $2.88 $296 - $576	-200 Reduced 16.67%	1,000 $1,000
Q2 2021 Jul 19, 2021	BUY	$6.33 - $9.91 $4,431 - $6,937	700 Added 140.0%	1,200 $7,000
Q4 2020 Jan 21, 2021	SELL	$6.47 - $7.9 $3,882 - $4,740	-600 Reduced 54.55%	500 $3,000
Q3 2020 Oct 27, 2020	BUY	$6.55 - $8.83 $5,895 - $7,947	900 Added 450.0%	1,100 $7,000
Q2 2020 Jul 22, 2020	SELL	$7.4 - $14.64 $740 - $1,464	-100 Reduced 33.33%	200 $1,000
Q2 2019 Aug 09, 2019	SELL	$9.35 - $11.41 $6,545 - $7,987	-700 Reduced 70.0%	300 $3,000
Q4 2018 Feb 05, 2019	BUY	$12.69 - $18.61 $11,421 - $16,749	900 Added 900.0%	1,000 $15,000
Q2 2018 Aug 10, 2018	SELL	$21.38 - $29.68 $8,552 - $11,872	-400 Reduced 80.0%	100 $2,000
Q4 2017 Jan 17, 2018	BUY	$19.0 - $23.09 $9,500 - $11,545	500	500 $10,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.